EVO (Evotec SE) Institutional Ownership : 2.50% (As of Apr. 10, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Evotec SE Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Evotec SE's institutional ownership is 2.50%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Evotec SE's Insider Ownership is 0.18%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Evotec SE's Float Percentage Of Total Shares Outstanding is 88.89%.

Evotec SE Institutional Ownership Historical Data

The historical data trend for Evotec SE's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Institutional Ownership Chart

Evotec SE Historical Data

The historical data trend for Evotec SE can be seen below:

	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Institutional Ownership	0.34	0.35	0.36	0.51	0.53	0.47	3.63	3.62	3.60	3.66

Evotec SE Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Evotec SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (NAS:EVO) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

EVOTF:USA 1EVT:Italy 0IRF:UK EVT:Germany EVT:Germany EVT:Germany EVT:Germany EVTA:Germany EVT:Bulgaria EVT:Austria

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.